Hong Kong’s leading biomedical and microbiome technology company, G-NiiB GenieBiome, is pleased to announce that a ground-breaking large-scale randomised, double-blind, placebo-controlled clinical trial (“the Trial”) conducted on the efficacy of SIM01, an oral microbiome immunity formula developed by a top-notch medical school in Hong Kong, involving 463 patients who had contracted novel virus, has strongly proved that the consumption of SIM01, an oral microencapsulated live bacteria formula, could significantly improve the gut microbiota after six months and lead to remarkable alleviation of post-novel virus sequelae, encompassing a range of symptoms affecting different systems and organs. The findings of the Trial were published yesterday in The Lancet Infectious Diseases, the most authoritative international medical journal in infectious diseases.